Tags

Type your tag names separated by a space and hit enter

Randomized placebo-controlled trial of a selective serotonin reuptake inhibitor in the treatment of nondepressed tinnitus subjects.
Psychosom Med. 2005 Nov-Dec; 67(6):981-8.PM

Abstract

OBJECTIVE

To assess the efficacy of a selective serotonin reuptake inhibitor (paroxetine) for relief of tinnitus.

DESIGN

One hundred twenty tinnitus sufferers participated in a randomized double-blind placebo-controlled trial. Paroxetine or placebo was increased to a maximally tolerated dose (up to 50 mg/day), and patients were treated for a total of 31 days at the maximal dose.

METHODS

Patients with chronic tinnitus were recruited from our university-based specialty clinic by referral from otolaryngologists and audiologists in the local community and by advertisement. Patients with psychotic or substance use disorders or suicidal ideation were excluded, as were those using psychoactive medications (this resulted in only 1 subject with major depression in the study) or any other medications that interact with paroxetine and those with inability to hear at one's tinnitus sensation level. Fifty-eight percent of patients were male, 92% were Caucasian, and the average age was 57.

OUTCOMES MEASURES

Tinnitus matching, the Tinnitus Handicap Questionnaire, the question: How severe (bothered, aggravating) is your tinnitus? Quality of Well-Being and other psychological questionnaires.

RESULTS

Paroxetine was not statistically superior to placebo on the following tinnitus measures (tinnitus matching, 5- or 10-db drop, Tinnitus Handicap Questionnaire, quality of well-being measures, how severe, how bothered, positive change). There was a significant improvement in the single item question, How aggravating is your tinnitus? for those in the paroxetine group compared with the placebo group.

CONCLUSIONS

These results suggest that the majority of individuals in this study did not benefit from paroxetine in a consistent fashion. Further work remains to be done to determine if subgroups of patients (e.g., those who tolerate higher doses, those who are depressed) may benefit.

Authors+Show Affiliations

Department of Psychiatry, University of California, San Diego School of Medicine, Veterans Administration San Diego Healthcare System, La Jolla, CA 92161, USA. skrobinson@ucsd.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16314604

Citation

Robinson, Shannon K., et al. "Randomized Placebo-controlled Trial of a Selective Serotonin Reuptake Inhibitor in the Treatment of Nondepressed Tinnitus Subjects." Psychosomatic Medicine, vol. 67, no. 6, 2005, pp. 981-8.
Robinson SK, Viirre ES, Bailey KA, et al. Randomized placebo-controlled trial of a selective serotonin reuptake inhibitor in the treatment of nondepressed tinnitus subjects. Psychosom Med. 2005;67(6):981-8.
Robinson, S. K., Viirre, E. S., Bailey, K. A., Gerke, M. A., Harris, J. P., & Stein, M. B. (2005). Randomized placebo-controlled trial of a selective serotonin reuptake inhibitor in the treatment of nondepressed tinnitus subjects. Psychosomatic Medicine, 67(6), 981-8.
Robinson SK, et al. Randomized Placebo-controlled Trial of a Selective Serotonin Reuptake Inhibitor in the Treatment of Nondepressed Tinnitus Subjects. Psychosom Med. 2005 Nov-Dec;67(6):981-8. PubMed PMID: 16314604.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Randomized placebo-controlled trial of a selective serotonin reuptake inhibitor in the treatment of nondepressed tinnitus subjects. AU - Robinson,Shannon K, AU - Viirre,Erik S, AU - Bailey,Kelly A, AU - Gerke,Melissa A, AU - Harris,Jeffery P, AU - Stein,Murray B, PY - 2005/11/30/pubmed PY - 2006/4/12/medline PY - 2005/11/30/entrez SP - 981 EP - 8 JF - Psychosomatic medicine JO - Psychosom Med VL - 67 IS - 6 N2 - OBJECTIVE: To assess the efficacy of a selective serotonin reuptake inhibitor (paroxetine) for relief of tinnitus. DESIGN: One hundred twenty tinnitus sufferers participated in a randomized double-blind placebo-controlled trial. Paroxetine or placebo was increased to a maximally tolerated dose (up to 50 mg/day), and patients were treated for a total of 31 days at the maximal dose. METHODS: Patients with chronic tinnitus were recruited from our university-based specialty clinic by referral from otolaryngologists and audiologists in the local community and by advertisement. Patients with psychotic or substance use disorders or suicidal ideation were excluded, as were those using psychoactive medications (this resulted in only 1 subject with major depression in the study) or any other medications that interact with paroxetine and those with inability to hear at one's tinnitus sensation level. Fifty-eight percent of patients were male, 92% were Caucasian, and the average age was 57. OUTCOMES MEASURES: Tinnitus matching, the Tinnitus Handicap Questionnaire, the question: How severe (bothered, aggravating) is your tinnitus? Quality of Well-Being and other psychological questionnaires. RESULTS: Paroxetine was not statistically superior to placebo on the following tinnitus measures (tinnitus matching, 5- or 10-db drop, Tinnitus Handicap Questionnaire, quality of well-being measures, how severe, how bothered, positive change). There was a significant improvement in the single item question, How aggravating is your tinnitus? for those in the paroxetine group compared with the placebo group. CONCLUSIONS: These results suggest that the majority of individuals in this study did not benefit from paroxetine in a consistent fashion. Further work remains to be done to determine if subgroups of patients (e.g., those who tolerate higher doses, those who are depressed) may benefit. SN - 1534-7796 UR - https://www.unboundmedicine.com/medline/citation/16314604/Randomized_placebo_controlled_trial_of_a_selective_serotonin_reuptake_inhibitor_in_the_treatment_of_nondepressed_tinnitus_subjects_ L2 - https://doi.org/10.1097/01.psy.0000188479.04891.74 DB - PRIME DP - Unbound Medicine ER -